Annales De Dermatologie Et De Venereologie最新文献

英文中文

Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata upadacitinib治疗伴有严重特应性皮炎和斑秃的双重疗效

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.03.010

B. Walls, Z. Reguiai

引用次数: 0

Reticulate skin pigmentation disorders: A morphologic approach. The concept of reticulate disorders of keratinization 网状皮肤色素沉着障碍:形态学方法。网状角化障碍的概念

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.03.013

C. Dieudonné, D. Lipsker

引用次数: 0

An uncommon case of epidermolysis bullosa acquisita associated with systemic sclerosis 一例罕见的大疱性表皮松解伴系统性硬化症

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.06.003

C. Labonne, D. Boutin, S. Baali, P. Roblot, E. Frouin, O. Renaud, E. Hainaut, M. Masson Regnault

引用次数: 0

Hidradenitis suppurativa: Influence of hormonal factors on disease activity in women in France 化脓性汗腺炎:激素因素对法国妇女疾病活动性的影响

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.06.005

A.-C. Fougerousse , Z. Reguiai , F. Maccari , P. Guillem , J.-L. Perrot , GEM ResoVerneuil

引用次数: 0

Predictors of initial incomplete resection of basal cell carcinoma of the face and neck 面部和颈部基底细胞癌初次不完全切除的预测因素。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.05.002

M. Borg, F. Amatore, J.-M. Foletti, B. Bertrand, N. Macagno, E. Delaporte, M.-A. Richard

引用次数: 0

Photodynamic therapy-induced flare of superficial pemphigus 光动力疗法引起的浅表性天疱疮耀斑

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.06.002

N. Kluger

引用次数: 0

The value of pharmaceutical expertise in the detection and management of drug interactions with targeted therapies in melanoma 药物专业知识在黑色素瘤靶向治疗药物相互作用检测和管理中的价值。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-12-01 DOI: 10.1016/j.annder.2023.05.006

B. Demarez, C. Gaudy, F. Amatore, F. Correard, C. Tabèle, M.-A. Richard

引用次数: 0

Genetics of adnexal tumors: An update 附件肿瘤遗传学：最新进展。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-09-01 DOI: 10.1016/j.annder.2023.03.003

T. Kervarrec , P. Sohier , D. Pissaloux , A. de la Fouchardiere , B. Cribier , M. Battistella , N. Macagno

Cutaneous adnexal tumors form a vast heterogeneous group that include frequent entities that are mostly benign, as well as rare tumors that are occasionally malignant. In contrast to cutaneous tumors arising from the interfollicular epidermis that develop as a result of accumulation of UV-induced DNA damage (basal cell carcinoma, squamous cell carcinoma), the oncogenesis of adnexal tumors is related to a broad spectrum of genetic mechanisms (e.g., point mutation, fusion genes, viral integration, etc.). In this setting, specific and recurrent genetic alterations have been progressively reported, and these allow better classification of these entities. For certain of them, immunohistochemical tools are now available, enabling precise integrated histological and molecular diagnosis since certain entities are linked to well-defined alterations. In this context, we aim in this review to summarize the main molecular tools currently available for the classification of adnexal tumors.

皮肤附件肿瘤形成了一个庞大的异质性群体，包括常见的良性实体，以及偶尔恶性的罕见肿瘤。与因紫外线诱导的DNA损伤积累而形成的毛囊间表皮皮肤肿瘤（基底细胞癌、鳞状细胞癌）不同，附件肿瘤的发生与广泛的遗传机制有关（如点突变、融合基因、病毒整合等），已经逐渐报道了特定的和反复发生的基因改变，这些改变可以更好地对这些实体进行分类。对于其中的某些实体，现在可以使用免疫组织化学工具，实现精确的组织学和分子综合诊断，因为某些实体与明确的改变有关。在这方面，我们的目的是在这篇综述中总结目前可用于附件肿瘤分类的主要分子工具。

引用次数: 1

Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice 细胞周期蛋白依赖性激酶CDK4和6抑制剂的皮肤毒性：临床实践的最新综述。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-09-01 DOI: 10.1016/j.annder.2022.11.013

V. Sibaud , P. Sollena

Cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have revolutionized the treatment of metastatic breast carcinoma. They currently form the first-line treatment, in combination with endocrine agents, for the management of locally advanced or metastatic hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the largest subtype of breast carcinoma.

CDK 4/6 inhibitors have shown comparable efficacy outcomes with predictable and manageable adverse events. In this setting, dermatologic toxicity appears to be relatively frequent, accounting for up to 15% of all reported adverse events. It is usually mild to moderate in intensity and does not normally constitute a dose-limiting toxicity. The range of dermatologic adverse events includes both non-specific entities (maculopapular rash, pruritus, alopecia) and more characteristic toxicities related to CDK4/6 inhibitors, such as vitiligo-like lesions or cutaneous lupus erythematosus. Finally, more severe or life-threatening skin reactions can occasionally occur. The main dermatologic manifestations associated with CDK4/6 inhibitors, as well as management thereof, are described in this comprehensive review.

细胞周期蛋白依赖性激酶（CDK）4/6抑制剂（palbociclib、ribociciclib和abemaciclib）彻底改变了转移性乳腺癌的治疗。目前，它们与内分泌药物联合形成了治疗局部晚期或转移性激素受体阳性（HR + ), 人表皮生长因子受体2阴性（HER2-）乳腺癌症是乳腺癌的最大亚型。CDK4/6抑制剂已显示出可预测和可控制的不良事件的可比疗效结果。在这种情况下，皮肤毒性似乎相对频繁，占所有报告不良事件的15%。它的强度通常为轻度至中度，通常不构成剂量限制毒性。皮肤科不良事件的范围包括非特异性实体（斑丘疹、瘙痒、脱发）和与CDK4/6抑制剂相关的更具特征性的毒性，如白癜风样病变或皮肤红斑狼疮。最后，偶尔会出现更严重或危及生命的皮肤反应。与CDK4/6抑制剂相关的主要皮肤病表现及其管理在本综述中进行了描述。

{"title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","authors":"V. Sibaud , P. Sollena","doi":"10.1016/j.annder.2022.11.013","DOIUrl":"10.1016/j.annder.2022.11.013","url":null,"abstract":"<div>Cyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have revolutionized the treatment of metastatic breast carcinoma. They currently form the first-line treatment, in combination with endocrine agents, for the management of locally advanced or metastatic hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the largest subtype of breast carcinoma.CDK 4/6 inhibitors have shown comparable efficacy outcomes with predictable and manageable adverse events. In this setting, dermatologic toxicity appears to be relatively frequent, accounting for up to 15% of all reported adverse events. It is usually mild to moderate in intensity and does not normally constitute a dose-limiting toxicity. The range of dermatologic adverse events includes both non-specific entities (maculopapular rash, pruritus, alopecia) and more characteristic toxicities related to CDK4/6 inhibitors, such as vitiligo-like lesions or cutaneous lupus erythematosus. Finally, more severe or life-threatening skin reactions can occasionally occur. The main dermatologic manifestations associated with CDK4/6 inhibitors, as well as management thereof, are described in this comprehensive review.</div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"150 3","pages":"Pages 208-212"},"PeriodicalIF":0.9,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study dupilumab在成人中度至重度特应性皮炎中的实际长期疗效：一项队列研究结果。

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2023-09-01 DOI: 10.1016/j.annder.2023.06.004

C. Guédon , M. Tauber , C. Linder , C. Paul , J. Shourick

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀